Toth Financial Advisory Corp cut its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 91.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 445 shares of the biotechnology company's stock after selling 4,890 shares during the period. Toth Financial Advisory Corp's holdings in Ascendis Pharma A/S were worth $77,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ASND. GF Fund Management CO. LTD. purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $174,000. GAMMA Investing LLC boosted its holdings in Ascendis Pharma A/S by 15,593.0% in the first quarter. GAMMA Investing LLC now owns 91,490 shares of the biotechnology company's stock worth $142,600,000 after purchasing an additional 90,907 shares during the period. Harbor Capital Advisors Inc. raised its stake in shares of Ascendis Pharma A/S by 1.3% during the first quarter. Harbor Capital Advisors Inc. now owns 85,960 shares of the biotechnology company's stock valued at $13,398,000 after purchasing an additional 1,087 shares in the last quarter. Pursue Wealth Partners LLC purchased a new position in Ascendis Pharma A/S in the 1st quarter worth about $226,000. Finally, Diversified Trust Co grew its stake in shares of Ascendis Pharma A/S by 3.4% in the 1st quarter. Diversified Trust Co now owns 46,548 shares of the biotechnology company's stock valued at $7,255,000 after buying an additional 1,510 shares in the last quarter.
Ascendis Pharma A/S Stock Performance
Shares of ASND traded down $1.26 during midday trading on Monday, hitting $196.42. 1,061,775 shares of the stock traded hands, compared to its average volume of 360,198. Ascendis Pharma A/S has a 1-year low of $118.03 and a 1-year high of $208.16. The firm has a market capitalization of $12.10 billion, a PE ratio of -38.07 and a beta of 0.39. The business's 50 day moving average price is $188.13 and its two-hundred day moving average price is $171.63.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analyst estimates of $163.17 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on ASND shares. UBS Group reiterated a "buy" rating and set a $307.00 target price (up from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Wall Street Zen lowered shares of Ascendis Pharma A/S from a "buy" rating to a "hold" rating in a research report on Friday, September 5th. Bank of America raised their target price on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Royal Bank Of Canada upped their target price on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the company an "overweight" rating in a report on Tuesday, August 19th. Fifteen investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Buy" and an average target price of $244.36.
Check Out Our Latest Research Report on ASND
Ascendis Pharma A/S Company Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading

Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.